文献速递肝病

非肝硬化HBeAg阴性患者停用富马酸替诺福韦二吡呋酯后的长期应答——FINITE研究

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
PubMed 文献 · J Hepatol · 2017-07-21

FINITE研究将已接受富马酸替诺福韦二吡呋酯(TDF)≥4年、HBV DNA抑制≥3.5年的非肝硬化HBeAg阴性患者随机分为停药组(n=21)和继续治疗组(n=21),随访144周。停药组62%维持停药至第144周,4例(19%)实现HBsAg清除,43%达到HBsAg清除或HBV DNA<2,000 IU/ml,未发现意外安全性问题。

要点

  • 停药组62%(n=13)维持停药至第144周。
  • 停药组4例(19%)实现HBsAg清除。
  • 第144周时停药组43%(n=9)达到HBsAg清除或HBV DNA<2,000 IU/ml。

核心结论

  • 这项对照研究显示,非肝硬化HBeAg阴性患者停用长期TDF治疗后有可能实现HBsAg清除和/或持续病毒学应答。

研究设计与样本

  • 非肝硬化HBeAg阴性患者,已接受TDF治疗≥4年且HBV DNA抑制≥3.5年,随机分配至停药组(n=21)或继续TDF单药治疗组(n=21)。
  • 治疗期间及治疗后随访144周,进行包括HBV DNA病毒载量、HBsAg和丙氨酸氨基转移酶(ALT)测定在内的标准实验室检查及不良事件报告。
  • 临床试验注册号:NCT01320943。

主要发现

  • 停药组62%(n=13)维持停药至第144周。
  • 停药组HBsAg中位变化为-0.59 log10 IU/ml(范围-4.49至0.02 log10 IU/ml),继续TDF治疗组为0.21 log10 IU/ml。
  • 停药组4例(19%)实现HBsAg清除。
  • 停药组患者病毒载量和ALT出现初期波动;第144周时,43%(n=9)达到HBsAg清除或HBV DNA<2,000 IU/ml。
  • 停用TDF治疗未发现意外安全性问题。

临床怎么用

  • 作者指出,这为无肝硬化的长期HBV抑制患者提供了在严格监测下停用核苷(酸)类似物(NA)治疗的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is currently no virological cure for chronic hepatitis B but successful nucleos(t)ide analogue (NA) therapy can suppress hepatitis B virus (HBV) DNA replication and, in some cases, result in HBsAg loss. Stopping NA therapy often leads to viral relapse and therefore life-long therapy is usually required. This study investigated the potential to discontinue tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative patients. METHODS: Non-cirrhotic HBeAg-negative patients who had received TDF for ≥4years, with suppressed HBV DNA for ≥3.5years, were randomly assigned to either stop (n=21) or continue (n=21) TDF monotherapy. Standard laboratory tests including HBV DNA viral load, HBsAg and alanine aminotransferase (ALT) measurements, and adverse event reporting were carried out during treatment and post-treatment follow-up for 144weeks. RESULTS: Of the patients who stopped TDF therapy, 62% (n=13) remained off-therapy to Week 144. Median HBsAg change in this group was -0.59log10IU/ml (range -4.49 to 0.02log10IU/ml) vs. 0.21log10IU/ml in patients who continued TDF therapy. Four patients (19%) achieved HBsAg loss. Patients stopping therapy had initial fluctuations in viral load and ALT; however, at Week 144, 43% (n=9) had either achieved HBsAg loss or had HBV DNA <2,000IU/ml. There were no unexpected safety issues identified with stopping TDF therapy. CONCLUSIONS: This controlled study demonstrated the potential for HBsAg loss and/or sustained virological response in non-cirrhotic HBeAg-negative patients stopping long-term TDF therapy. Lay summary: Nucleos(t)ide analogue (NA) is usually a life-long therapy for HBV patients. This randomised controlled study investigated the discontinuation of tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative patients. Of the patients who stopped TDF therapy, 62% remained off-therapy to Week 144, of which 43% of patients had achieved either HBsAg loss or HBV DNA <2,000IU/ml. This offers a potential for long-term HBV-suppressed patients without cirrhosis to stop NA therapy under strict surveillance. Clinical trial number: NCT01320943.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Berg T, Simon KG, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017. PMID: 28736139. doi:10.1016/j.jhep.2017.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。